Alliance Pharma PLC AGM Statement (5689A)
May 25 2023 - 1:00AM
UK Regulatory
TIDMAPH
RNS Number : 5689A
Alliance Pharma PLC
25 May 2023
For immediate release 25 May 2023
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
AGM statement
Alliance Pharma plc (AIM: APH), the international consumer
healthcare company, will hold its Annual General Meeting ("AGM") at
09:00am this morning. At the meeting, the Group's Chair, David
Cook, will make the following statement:
"Sales for the first four months of the year are ahead of the
equivalent period in 2022.
"In-market demand for Kelo-Cote(TM) in China has continued the
recovery we referenced in our preliminary results announcement in
March and is building in-line with our expectations.
"Whilst the business is on track to meet the Board's full year
expectations for revenue and adjusted EBITDA, adverse currency
movements, particularly the recent strengthening of UK sterling
against the US dollar, and the rising interest rate environment,
mean that full year adjusted profit before tax is expected to be
marginally below current expectations.
"Further detail will be provided in the interim trading update
scheduled for 18 July 2023."
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser + 44 (0)20 7260
and Joint Broker) 1000
Freddie Barnfield / Duncan Monteith / Sher
Shah
+ 44 (0)20 7597
Investec Bank plc (Joint Broker) 5970
Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company. Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMNKQBDOBKDDPB
(END) Dow Jones Newswires
May 25, 2023 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024